Neoplasm by Morphology

In a non-small cell lung cancer patient with acquired crizotinib resistance, the tumor had an ALK gene rearrangement and an ALK G1202R co-mutation. The ALK G1202R tumor was reported to be refractory t… (full text at CIViC)

PMID 23729361 · Gainor et al., 2013 · Open in CIViC

This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One ALK+ patient had a novel fusion between… (full text at CIViC)

PMID 22235099 · Doebele et al., 2012 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated resistance to crizotinib treatment (IC50: 871.75… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

The NSCLC cell line MGH021-4, harboring SQSTM1-ALK G1269A, was 6 times more sensitive to ceritinib (80nM GI50) than crizotinib (500 nM) in proliferation assays and caused notable reductions in phospho… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

In a non-small cell lung cancer patient with acquired crizotinib resistance, the tumor had an ALK gene rearrangement and an ALK G1269A co-mutation. The ALK G1269A tumor was reported to be refractory t… (full text at CIViC)

PMID 23729361 · Gainor et al., 2013 · Open in CIViC

Analysis of 48 lung adenocarcinomas identified novel ALK mutations in six tumours, including S413N in the MAM1 domain, V597A in the MAM2, H694R in an undefined region, G881D in the glycine-rich domain… (full text at CIViC)

PMID 21847362 · Wang et al., 2011 · Open in CIViC

Analysis of 48 lung adenocarcinomas identified novel ALK mutations in six tumours, including S413N in the MAM1 domain, V597A in the MAM2, H694R in an undefined region, G881D in the glycine-rich domain… (full text at CIViC)

PMID 21847362 · Wang et al., 2011 · Open in CIViC

The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again … (full text at CIViC)

PMID 25228534 · Katayama et al., 2014 · Open in CIViC

A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases. ALK rearrangement was verified via FISH. She was treated with crizotinib at 250 mg twice daily but discontinu… (full text at CIViC)

PMID 25736571 · Ou et al., 2015 · Open in CIViC

Case study describes a female (age 58) never-smoker presenting with stage IV NSCLC with an ALK rearrangement (confirmed by fish). Patient was treated with crizotinib (partial response) and alectinib (… (full text at CIViC)

PMID 25393796 · Ou et al., 2014 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1152P co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

In an in vitro study, cell lines expressing NPM-ALK L1196Q, K299CR06 (endogenous expression) and Ba/F3 (overexpression), demonstrated resistance to crizotinib treatment (IC50: 948 nmol/L and 212 nmol/… (full text at CIViC)

PMID 23239810 · Ceccon et al., 2013 · Open in CIViC

In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted t… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

In a metastatic EML4-ALK rearranged non-small cell lung carcinoma patient harboring ALK C1156Y (a known crizotinib resistance mutation) and ALK L1198F co-mutations, ALK L1198F was associated with rese… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK L1198P co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 21948233 · Heuckmann et al., 2011 · Open in CIViC

In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib. Of 114 NSCLC patients treated with at least 400 mg/daily ceriti… (full text at CIViC)

PMID 24670165 · Shaw et al., 2014 · Open in CIViC

In this phase II, open-label, single-arm trial, 276 patients with a histologically or cytologically confirmed diagnosis of metastatic non-small-cell lung cancer that carried either an ALK or ROS1 gene… (full text at CIViC)

PMID 30413378 · Solomon et al., 2018 · Open in CIViC

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK (a known sensitizing alteration to crizotinib) and an ALK R1192P co-mutation, demonstrated resistance to crizotinib treatment (IC50: 421.5 … (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

In a patient with nasal type extranodal NK/T-cell lymphoma harboring ALK R214H mutation, ALK R214H was associated with response to crizotinib monotherapy. Prior to identification of the ALK R214H muta… (full text at CIViC)

PMID 27594191 · Thanarajasingam et al., 2016 · Open in CIViC

In a prospective study (NCT01283516) of 130 cancer patients, a non-small cell lung cancer patient harboring a S1206Y mutation in the ALK portion of the ALK rearrangement was associated with a 60% resp… (full text at CIViC)

PMID 24670165 · Shaw et al., 2014 · Open in CIViC

In a case report of a patient with metastatic melanoma harhouring an in-frame ANO10-RAF1 fusion, a MEK inhibitor (trametinib) treatment resulted in brief, but significant, tumor regression and symptom… (full text at CIViC)

PMID 35135096 · Kim et al., 2018 · Open in CIViC

Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.

PMID 22440753 · Waaler et al., 2012 · Open in CIViC

In a phase 3 trial (NCT03785964) involving 142 adults with progressing desmoid tumors, the gamma-secretase inhibitor nirogacestat demonstrated a significant progression-free survival benefit compared … (full text at CIViC)

PMID 36884323 · Gounder et al., 2023 · Open in CIViC

Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC)

PMID 31068372 · Jones et al., 2019 · Open in CIViC

In an open-label, phase II trial, 18 patients with histiocytosis, including two patients with Langerhans cell histiocytosis, of any mutational status were enrolled. Patients received cobimetinib at a … (full text at CIViC)

PMID 30867592 · Diamond et al., 2019 · Open in CIViC

In an open-label, phase II trial, 18 patients with histiocytosis, including 12 patients with Erdheim-Chester disease, one patient with ARAF S225V, and one patient with ARAF P216A, of any mutational st… (full text at CIViC)

PMID 30867592 · Diamond et al., 2019 · Open in CIViC

In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.

PMID 24569458 · Imielinski et al., 2014 · Open in CIViC

Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.

PMID 24569458 · Imielinski et al., 2014 · Open in CIViC

47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC)

PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC

47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tum… (full text at CIViC)

PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC

In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC)

PMID 20942669 · Wiegand et al., 2010 · Open in CIViC

This study sequenced 73 DLBCL tumors (34 with matched constitutional DNA) and reported 322 genes they deemed recurrently mutated. Only genes that have been confirmed by other similar studies were adde… (full text at CIViC)

PMID 23292937 · Zhang et al., 2013 · Open in CIViC

Reported as significantly mutated in BL per the cited study. An arbitrarily selected variant from the study is included here.

PMID 30617194 · Grande et al., 2019 · Open in CIViC

This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohis… (full text at CIViC)

PMID 25628030 · Park et al., 2015 · Open in CIViC

Mutation of ARID2 in Hepatocellular Carcinoma (HCC) is often seen. There is about 6/16 of the truncated mutations found at the C2H2 domain (zinc finger) and about 16/24 mutations show that this domain… (full text at CIViC)

PMID 32071245 · Jiang et al., 2020 · Open in CIViC

LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.

PMID 12517791 · Hara et al., 2003 · Open in CIViC